Scilex Holding

AI Score

0

Unlock

0.44
-0.00 (-0.72%)
At close: Jan 14, 2025, 3:59 PM
0.44
0.43%
Pre-market Jan 15, 2025, 06:19 AM EST
undefined%
Bid 0.41
Market Cap 104.77M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.44
PE Ratio (ttm) -0.3
Forward PE n/a
Analyst Buy
Ask 0.47
Volume 680,987
Avg. Volume (20D) 2,242,931
Open 0.44
Previous Close 0.44
Day's Range 0.42 - 0.46
52-Week Range 0.38 - 2.63
Beta undefined

About SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...

Sector Healthcare
IPO Date Mar 5, 2021
Employees 113
Stock Exchange NASDAQ
Ticker Symbol SCLX

Analyst Forecast

According to 3 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 2867.36% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Scilex Holding is scheduled to release its earnings on Jan 28, 2025, before market opens.
Analysts project revenue of $18.04M, reflecting a 78.31% YoY growth and earnings per share of -0.1, making a -84.13% decrease YoY.
1 month ago · Source
-12.75%
Scilex Holding shares are trading lower after the ... Unlock content with Pro Subscription
1 month ago · Source
-5.57%
Scilex shares are trading lower after the company announced it received a receipt of notice from Nasdaq for its failure to file its quarterly report ending September 30.